Search
forLearn
5 / 16 resultslearn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn Stemoxydine
chemical from L'Oreal that encourages hair to enter growth phase
learn Mesotherapy
technique to inject very small amounts of beneficial chemicals into the scalp
learn Vascular Endothelial Growth Factor
Research
5 / 1000+ resultsresearch Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata
Ritlecitinib demonstrates clinically meaningful and sustained efficacy for over 1 year in treating alopecia areata (AA) in patients aged 12 years and older. The treatment also has a favorable safety and tolerability profile, supporting its long-term use.
research Adverse Effects of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Literature Review
Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
research Evaluating Current and Emerging JAK Inhibitors for Alopecia Areata: A Narrative Review
JAK inhibitors show promise for treating alopecia areata but have serious side effects.
research Exploring Novel Management Options for Alopecia Areata
JAK inhibitors can help treat alopecia areata but have risks and high costs.
research The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review
Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
Community Join
5 / 1000+ resultscommunity Kintor long term safety phase 3
Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.
community Breezula 6 Month Topline Phase III Results Released
Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.
community KX-826: Long-Term Safety Results are out!
KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.
community Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
community I am a dermatologist with a clinical interest in alopecia. AMA
In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.